Following reports by the Bloomberg news service, on Friday Ireland-based drugmaker Shire (LSE: SHP) confirmed that it has held a meeting with representatives of AbbVie (NYSE: ABBV), which is pursuing an unsolicited acquisition of the company.
Shire noted: “This statement is being made by Shire without the prior agreement or approval of AbbVie. A further update will be made when appropriate. Shareholders are strongly advised to take no action in relation to AbbVie’s proposal. There can be no certainty that any firm offer will be made nor as to the terms on which any firm offer might be made.”
AbbVie’s first three offer for Shire have so far been rejected as not adequately reflecting the value of the company, and Shire’s latest statement comes after it received a fourth, even higher offer of £51.15 per share, comprising of £22.44 in cash and 0.8568 ordinary shares, and 11% higher than the prior bid. This latest offer values Shire, a maker of neurological and rare diseases treatments, at some $51.5 billion.
Shire’s shares rose 5.9% to £48.70 by close of London trading on Friday, while AbbVie slipped 0.7% to $54.96 in New York.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze